Probiodrug, a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, has appointed Dr. Michael Schaeffer as executive vice president of business and strategy. Prior to joining Probiodrug, Michael was the founder and managing director of biotech companies, CRELUX and SiREEN. Following the acquisition of CRELUX by WuXiAppTec in 2016, he was responsible for integrating CRELUX into the leading global CRO with over 18,000 employees based in Shanghai.
